In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin

被引:36
作者
Riley, RJ [1 ]
Howbrook, D [1 ]
机构
[1] Astra Charnwood, DMPK Res, Dept Phys & Metab Sci, Loughborough, Leics, England
关键词
N-methyl-C-14]-erythromycin; human CYP3A4; human liver microsomes; ketoconazole;
D O I
10.1016/S1056-8719(97)00103-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the N-demethylation of erythromycin has found widespread use in a noninvasive assay with which to phenotype hepatic CYP3A function, currently, the routine in vitro analysis of erythromycin N-demethylase activity relies on the quantitation of liberated formaldehyde by relatively labor-intensive and insensitive colorimetric or fluorimetric detection. This report describes the development of a rapid, sensitive, and reproducible radioassay for human CYP3A4 using solid-phase extraction (SPE). The kinetics of erythromycin N-demethylation were best described by a one-site Michaelis-Menten model with autoinhibition and the apparent kinetic parameters for pooled human liver microsomes (HLM; Km = 88 mu M, Vmax = 345 pmol/min/mg) and expressed CYP3A4 (Km = 33 mu M, Vmax = 130 pmol/min/ mg) were in good agreement. Erythromycin N-demethylase activity was found to vary 14-fold in HLM and correlated with the rate of testosterone 6 beta-hydroxylation (r(2) = 0.92, p < 0.001; N = 9). Ketoconazole was a potent inhibitor of the N-demethylation of erythromycin, and the estimated IC,, value (104 +/- 23 nM) agreed well with that obtained using testosterone as a probe for CYP3A (71 +/- 4 nM). The addition of this radioassay to those established for human CYP1A2, 2C9, 2D6, and 2E1 and its subsequent automation should enable the routine use of this methodology in the analysis of CYP-dependent reactions. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 30 条
[1]   CISAPRIDE AND TORSADES-DE-POINTES [J].
AHMAD, SR ;
WOLFE, SM .
LANCET, 1995, 345 (8948) :508-508
[2]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[3]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[4]   THE ROLE OF CYTOCHROME-P4502D6 IN THE METABOLISM OF PAROXETINE BY HUMAN LIVER-MICROSOMES [J].
BLOOMER, JC ;
WOODS, FR ;
HADDOCK, RE ;
LENNARD, MS ;
TUCKER, GT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (05) :521-523
[5]   DETERMINATION OF P4501A2 ACTIVITY IN HUMAN LIVER-MICROSOMES USING [3-C-14-METHYL] CAFFEINE [J].
BLOOMER, JC ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (09) :917-927
[6]   TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CONNER, DP ;
MULLIN, JC ;
CANTILENA, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518
[7]   EFFECT OF AGE AND GENDER ON THE ACTIVITY OF HUMAN HEPATIC-CYP3A [J].
HUNT, CM ;
WESTERKAM, WR ;
STAVE, GM .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (02) :275-283
[8]   Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data [J].
Iwatsubo, T ;
Hirota, N ;
Ooie, T ;
Suzuki, H ;
Shimada, N ;
Chiba, K ;
Ishizaki, T ;
Green, CE ;
Tyson, CA ;
Sugiyama, Y .
PHARMACOLOGY & THERAPEUTICS, 1997, 73 (02) :147-171
[9]   THE ERYTHROMYCIN BREATH TEST SELECTIVELY MEASURES P450IIIA IN PATIENTS WITH SEVERE LIVER-DISEASE [J].
LOWN, K ;
KOLARS, J ;
TURGEON, K ;
MERION, R ;
WRIGHTON, SA ;
WATKINS, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :229-238
[10]   THE ERYTHROMYCIN BREATH TEST PREDICTS THE CLEARANCE OF MIDAZOLAM [J].
LOWN, KS ;
THUMMEL, KE ;
BENEDICT, PE ;
SHEN, DD ;
TURGEON, DK ;
BERENT, S ;
WATKINS, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (01) :16-24